News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

APT Pharmaceutical LLC Acquires Exclusive Worldwide Rights to Develop and Commercialize Inhalable Cyclosporine to Prevent Lung Transplant Rejection


6/5/2007 1:27:36 PM

FOSTER CITY, Calif.--(BUSINESS WIRE)--APT, a specialty drug development company focused on effective treatments for significant unmet medical needs, announced today that it has entered into an exclusive licensing agreement with Novartis Pharma AG for the worldwide rights to develop and commercialize an inhalable form of cyclosporine for the prevention and treatment of lung transplant rejection.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES